Zobrazeno 1 - 10
of 163
pro vyhledávání: '"Tomotaka KAWAYAMA"'
Autor:
Shigeo Muro, Tomotaka Kawayama, Hisatoshi Sugiura, Munehiro Seki, Elizabeth A. Duncan, Karin Bowen, Jonathan Marshall, Ayman Megally, Mehul Patel
Publikováno v:
Respiratory Research, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Background Japanese guidelines recommend triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) therapy in patients with chronic obstructive pulmonary disease (COPD) and no concurrent asth
Externí odkaz:
https://doaj.org/article/991826ae90dd4b509303175b73806b5b
Autor:
Klaus F. Rabe, Fernando J. Martinez, Surya P. Bhatt, Tomotaka Kawayama, Borja G. Cosio, Robert M. Mroz, Maarten M. Boomsma, Helene Goulaouic, Michael C. Nivens, Michel Djandji, Xavier Soler, Ying Liu, Matthew P. Kosloski, Christine R. Xu, Nikhil Amin, Heribert Staudinger, David J. Lederer, Raolat M. Abdulai
Publikováno v:
ERJ Open Research, Vol 10, Iss 5 (2024)
Background Accumulating data implicate interleukin (IL)-33, a proinflammatory cytokine released locally upon epithelial cell damage, in the pathogenesis of COPD. In a phase 2 study, itepekimab, a human monoclonal antibody against IL-33, reduced exace
Externí odkaz:
https://doaj.org/article/3bd4edef6ab44bf1a5e1e7bec238bd0c
Autor:
Tomotaka Kawayama, Kenichi Takahashi, Toshikazu Ikeda, Kenya Fukui, Naoyuki Makita, Naoki Tashiro, Junpei Saito, Toshihiro Shirai, Hiromasa Inoue
Publikováno v:
Allergology International, Vol 73, Iss 1, Pp 71-80 (2024)
Background: Although clinical trials including asthma and COPD patients have revealed much about exacerbation frequencies, most studies are limited in that they recruited patients only with a clear diagnosis of one disease or the other, based on conv
Externí odkaz:
https://doaj.org/article/89df5a22e1044987920d76249ea8f630
Autor:
Kazuya Ichikado, Toru Kotani, Yasuhiro Kondoh, Hideaki Imanaka, Takeshi Johkoh, Kiminori Fujimoto, Shin Nunomiya, Tomotaka Kawayama, Masanori Sawada, Eric Jenkins, Sadatomo Tasaka, Satoru Hashimoto
Publikováno v:
Stem Cell Research & Therapy, Vol 14, Iss 1, Pp 1-13 (2023)
Abstract Background Acute respiratory distress syndrome (ARDS) is a life-threatening inflammatory lung injury with high mortality; no approved medication exists. Efficacy and safety of bone marrow–derived, allogeneic, multipotent adult progenitor c
Externí odkaz:
https://doaj.org/article/b6ca49e8a2374014a50bd530f6672e40
Autor:
Jun Sasaki, Takashi Kinoshita, Misa Sudou, Takayuki Horii, Reiko Takaki, Masahiro Mitsuoka, Masaki Tominaga, Tomotaka Kawayama, Tomoaki Hoshino
Publikováno v:
Respirology Case Reports, Vol 11, Iss 12, Pp n/a-n/a (2023)
Abstract Cryptococcosis typically manifests as pulmonary lesions, with endobronchial lesions occurring rarely. Inhaled corticosteroids (ICS) may be a risk factor for cryptococcosis of the larynx but not of the bronchi. Here, we report a case involvin
Externí odkaz:
https://doaj.org/article/e3fde4db508641d799300e7c272730a7
Autor:
Hiromasa Inoue, Ayako Takamori, Atsushi Kawaguchi, Takashi Kinoshita, Kazuhiro Yatera, Koichiro Takahashi, Tomotaka Kawayama, Hiroki Tashiro, Koichi Takagi, Kei Yamasaki, Kentaro Machida
Publikováno v:
BMJ Open Respiratory Research, Vol 10, Iss 1 (2023)
Introduction Bronchodilators, including long-acting muscarinic antagonists (LAMA) and long-acting beta 2 agonists (LABA), are the main treatments for chronic obstructive pulmonary disease (COPD). The efficacy of triple therapy (inhaled corticosteroid
Externí odkaz:
https://doaj.org/article/2d8ed3137ae248aba734db9752590a90
Autor:
Akira Koarai, Mitsuhiro Yamada, Tomohiro Ichikawa, Naoya Fujino, Tomotaka Kawayama, Hisatoshi Sugiura
Publikováno v:
Respiratory Research, Vol 22, Iss 1, Pp 1-11 (2021)
Abstract Background Recently, the addition of inhaled corticosteroid (ICS) to long-acting muscarinic antagonist (LAMA) and long-acting beta-agonist (LABA) combination therapy has been recommended for patients with COPD who have severe symptoms and a
Externí odkaz:
https://doaj.org/article/6f9ca0cc973c410a949bf693cfbc9572
Autor:
Chiyo Yano, Tomotaka Kawayama, Takashi Kinoshita, Yoshihisa Tokunaga, Jun Sasaki, Yuki Sakazaki, Masanobu Matsuoka, Haruki Imaoka, Mamoru Nishiyama, Kazuko Matsunaga, Kyoji Furukawa, Tomoaki Hoshino
Publikováno v:
Allergology International, Vol 70, Iss 2, Pp 201-207 (2021)
Background: Obesity is a risk factor for severe and difficult-to-treat asthma. However, the impact of different physiques on long-term outcomes is poorly understood. We aimed to investigate the correlation between obesity and asthma-associated long-t
Externí odkaz:
https://doaj.org/article/b559e2b3f7334a1a8ee598f01793cc42
Autor:
Akira Koarai, Hisatoshi Sugiura, Mitsuhiro Yamada, Tomohiro Ichikawa, Naoya Fujino, Tomotaka Kawayama, Masakazu Ichinose
Publikováno v:
BMC Pulmonary Medicine, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background Inhaled bronchodilators including long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) play a central role in the treatment of stable chronic obstructive pulmonary disease (COPD). However, it is still uncle
Externí odkaz:
https://doaj.org/article/cbf94b9b2a4643f1bcb56951ac902675
Autor:
Jun Sasaki, Masanobu Matsuoka, Takashi Kinoshita, Takayuki Horii, Shingo Tsuneyoshi, Daiki Murata, Reiko Takaki, Masaki Tominaga, Mio Tanaka, Haruhiko Maruyama, Tomotaka Kawayama, Tomoaki Hoshino
Publikováno v:
Medicina, Vol 59, Iss 1, p 137 (2023)
Paragonimiasis caused by trematodes belonging to the genus Paragonimus is often accompanied by chronic respiratory symptoms such as cough, the accumulation of sputum, hemoptysis, and chest pain. Prolonged symptoms, including respiratory symptoms, aft
Externí odkaz:
https://doaj.org/article/308d661090ce429fa1fb030ff7716456